BEOVU
Total Payments
$110.7M
Transactions
9,668
Doctors
2,344
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $126,548 | 47 | 3 |
| 2023 | $2.7M | 226 | 11 |
| 2022 | $7.1M | 527 | 155 |
| 2021 | $23.0M | 2,264 | 884 |
| 2020 | $53.4M | 2,505 | 1,110 |
| 2019 | $24.2M | 4,092 | 1,528 |
| 2018 | $61,819 | 6 | 2 |
| 2017 | $3,430 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $106.5M | 1,911 | 96.2% |
| Consulting Fee | $2.7M | 512 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.0M | 278 | 0.9% |
| Food and Beverage | $228,213 | 6,289 | 0.2% |
| Travel and Lodging | $170,501 | 670 | 0.2% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $22,360 | 4 | 0.0% |
| Education | $703.01 | 4 | 0.0% |
Payments by Type
Research
$106.5M
1,911 transactions
General
$4.2M
7,757 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER RANDOMIZED DOUBLE MASKED PHASE 3A STUDY TO ASSESS SAFETY AND EFFICACY OF BROLUCIZUMAB 6 MG Q4 WEEKS COMPARED TO AFLIBERCEPT 2 MG Q4 WEEKS IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION NAMD WITH PERSISTENT RETINAL FLUID | Novartis Pharmaceuticals Corporation | $42.3M | 5 |
| A 12-MONTH, 2-ARM, RANDOMIZED, DOUBLE-MASKED, MULTICENTER PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VS. AFLIBERCEPT IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA (KINGFISHER) | Novartis Pharmaceuticals Corporation | $23.0M | 0 |
| A TWO YEAR, RANDOMIZED, DOUBLE MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA | Novartis Pharmaceuticals Corporation | $11.8M | 0 |
| A 96-WEEK, TWO-ARM, RANDOMIZED, SINGLE-MASKED, MULTI-CENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB 6 MG COMPARED TO PANRETINAL PHOTOCOAGULATION LASER IN PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY | Novartis Pharmaceuticals Corporation | $9.1M | 0 |
| A RANDOMIZED DOUBLE-MASKED, PHASE III STUDY ASSESSING BROLUCIZUMAB INTRAVITREAL INJECTIONS VERSUS AFLIBERCEPT IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA (ME) SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (CRVO) | Novartis Pharmaceuticals Corporation | $6.0M | 0 |
| AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSI | Novartis Pharmaceuticals Corporation | $4.2M | 0 |
| A 64-WEEK, PHASE 3B, MULTI-CENTER STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB 6MG COMPARED TO AFLIBERCEPT 2MG IN A TREAT TO CONTROL REGIMEN IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | Novartis Pharmaceuticals Corporation | $3.3M | 0 |
| AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION (RAPTOR) | Novartis Pharmaceuticals Corporation | $2.6M | 0 |
| A 96-week, Two-arm, Randomized, Single-masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab 6 mg Compared to Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy | Novartis Pharmaceuticals Corporation | $2.3M | 0 |
| A 12-MONTH, 2-ARM, RANDOMIZED, DOUBLE-MASKED, MULTICENTER PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VS. AFLIBERCEPT IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO DIABETIC MACULAR EDEMA (KINGFISHER) | NOVARTIS PHARMACEUTICALS CORPORATION | $431,087 | 0 |
| A RANDOMIZED DOUBLE-MASKED, PHASE III STUDY ASSESSING BROLUCIZUMAB INTRAVITREAL INJECTIONS VERSUS AFLIBERCEPT IN PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA (ME) SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION (CRVO) | NOVARTIS PHARMACEUTICALS CORPORATION | $254,651 | 0 |
| A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema | Novartis Pharmaceuticals Corporation | $162,278 | 0 |
| AN EIGHTEEN-MONTH, TWO-ARM, RANDOMIZED, DOUBLE MASKED, MULTICENTER, PHASE III STUDY ASSESSING THE EFFICACY AND SAFETY OF BROLUCIZUMAB VERSUS AFLIBERCEPT IN ADULT PATIENTS WITH VISUAL IMPAIRMENT DUE TO MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSI | NOVARTIS PHARMACEUTICALS CORPORATION | $144,378 | 0 |
| A 64-week, phase 3b, multi-center study assessing the efficacy and safety of brolucizumab 6mg compared to aflibercept 2mg in a treat to control regimen in patients with neovascular age-related macular degeneration | Novartis Pharmaceuticals Corporation | $98,340 | 0 |
| CRTH258A2301 | Novartis Pharmaceuticals Corporation | $94,872 | 8 |
| A 56-WEEK PHASE IIIB/IV, OPEN-LABEL, ONE-ARM EXTENSION STUDY TO ASSESS THE EFFICACY AND SAFETY OF BROLUCIZUMAB 6 MG IN A TREAT-TO-CONTROL REGIMEN WITH MAXIMUM TREATMENT INTERVALS UP TO 20 WEEKS FOR THE TREATMENT OF PATIENTS WITH NEOVASCULAR AGE-RELATED MA | Novartis Pharmaceuticals Corporation | $86,031 | 0 |
| A 24-WEEK DOUBLE MASKED MULTICENTER TWO ARM EXTENSION STUDY TO COLLECT SAFETY AND EFFICACY DATA ON BROLUCIZUMAB 6 MG DRUG PRODUCT INTENDED FOR COMMERCIALIZATION IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION WHO HAVE COMPLETED THE CRTH258A2 | Novartis Pharmaceuticals Corporation | $74,409 | 0 |
| A 56-week phase IIIb/IV, open-label, one-arm extension study to assess the efficacy and safety of brolucizumab 6 mg in a Treat-to-Control regimen with maximum treatment intervals up to 20 weeks for the treatment of patients with neovascular age-related macular degeneration who have completed the CRTH258A2303 study (TALON) | Novartis Pharmaceuticals Corporation | $73,132 | 0 |
| Publication support research related | Novartis Pharma AG | $72,898 | 13 |
| AN OPEN-LABEL, SINGLE-ARM, MULTICENTER PHASE IIIB STUDY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TO EVALUATE THE SAFETY OF BROLUCIZUMAB 6 MG IN PREFILLED SYRINGE. | Novartis Pharmaceuticals Corporation | $50,316 | 0 |
Top Doctors Receiving Payments for BEOVU
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Beverly Hills, CA | $106.7M | 1,789 |
| , MD | Ophthalmology | Cleveland, OH | $225,601 | 65 |
| , M.D | Ophthalmology | Cleveland, OH | $220,806 | 31 |
| , M.D | Ophthalmology | Reno, NV | $188,661 | 98 |
| Jeffrey Heier | Ophthalmology | Boston, MA | $175,341 | 33 |
| , MD | Ophthalmology | Cleveland, OH | $163,665 | 28 |
| , M.D | Retina Specialist | St Petersburg, FL | $130,404 | 67 |
| , M.D | Ophthalmology | Phoenix, AZ | $111,405 | 86 |
| , MD, PHD | Retina Specialist | Houston, TX | $110,253 | 38 |
| , MD | Ophthalmology | Miami, FL | $97,254 | 18 |
| , MD | Specialist | Boston, MA | $91,378 | 48 |
| , M.D | Ophthalmology | San Antonio, TX | $89,807 | 56 |
| Seenu Hariprasad | Ophthalmology | Burr Ridge, IL | $88,752 | 46 |
| , MD | Ophthalmology | Cleveland, OH | $87,464 | 42 |
| , M.D | Ophthalmology | Beachwood, OH | $76,084 | 57 |
| , MD | Ophthalmology | Pasadena, CA | $72,674 | 19 |
| , M.D | Retina Specialist | West Des Moines, IA | $61,556 | 47 |
| , M.D | Retina Specialist | Santa Barbara, CA | $57,332 | 50 |
| , M.D | Ophthalmology | Boulder, CO | $54,558 | 31 |
| , M.D | Ophthalmology | Santa Barbara, CA | $48,327 | 52 |
| , M.D | Ophthalmology | Chesterfield, MO | $47,898 | 25 |
| , M.D | Ophthalmology | Houston, TX | $46,235 | 18 |
| , M.D | Ophthalmology | Plano, TX | $44,491 | 44 |
| , M.D | Ophthalmology | Springfield, MA | $44,196 | 28 |
| , M.D | Ophthalmology | Owings Mills, MD | $43,248 | 28 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $108.6M
- NOVARTIS PHARMACEUTICALS CORPORATION $1.3M
- Novartis Pharma AG $837,335
Product Information
- Type Drug
- Total Payments $110.7M
- Total Doctors 2,344
- Transactions 9,668
About BEOVU
BEOVU is a drug associated with $110.7M in payments to 2,344 healthcare providers, recorded across 9,668 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2024. In 2024, $126,548 was paid across 47 transactions to 3 doctors.
The most common payment nature for BEOVU is "Unspecified" ($106.5M, 96.2% of total).
BEOVU is associated with 20 research studies, including "A MULTICENTER RANDOMIZED DOUBLE MASKED PHASE 3A STUDY TO ASSESS SAFETY AND EFFICACY OF BROLUCIZUMAB 6 MG Q4 WEEKS COMPARED TO AFLIBERCEPT 2 MG Q4 WEEKS IN PATIENTS WITH NEOVASCULAR AGE RELATED MACULAR DEGENERATION NAMD WITH PERSISTENT RETINAL FLUID" ($42.3M).